Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624917 | 0.90 | RXFP1 (0.47) | KMT2ARXFP1MAPTMEN1LMNA | |
| SCHEMBL4625337 | 0.90 | RXFP1 (0.56) | KMT2ARXFP1MAPTMEN1LMNA | |
| SCHEMBL29606235 | 0.90 | RXFP1 (0.47) | KMT2ARXFP1MAPTMEN1LMNA | |
| SCHEMBL4626752 | 0.87 | KMT2A (0.50) | KMT2ARXFP1MAPTLMNAPKM | |
| SCHEMBL4626114 | 0.84 | MAPT (0.46) | KMT2AMAPTALOX5HTTKDM4E | |
| SCHEMBL8299924 | 0.81 | ALOX5 (0.47) | KMT2ARXFP1MAPTALOX5HTT | |
| SCHEMBL29618234 | 0.81 | ALOX5 (0.47) | KMT2ARXFP1MAPTALOX5HTT | |
| SCHEMBL4625115 | 0.77 | ALOX5 (0.44) | KMT2AMAPTALOX5HTTALDH1A1 | |
| SCHEMBL4625110 | 0.77 | ALOX5 (0.55) | KMT2AMAPTMEN1LMNAALOX5 | |
| SCHEMBL5565836 | 0.76 | ALOX5 (0.50) | KMT2AL3MBTL1MAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682076-A4 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS INC (US) | 2008-02-06 | — | — | EP | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1682076-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1635812-A2 | BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Fulcrum Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041904-A2 | INHIBITORS OF CORONAVIRUS PROTEASE AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005004799-A2 | β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | FULCRUM PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267071-A1 | Inhibitors of coronavirus protease and methods of use thereof | ACE, ACE2, CTRL | KMT2A 3018/4885L3MBTL1 968/4885RXFP1 4111/4885 |
| US-20050124580-A1 | Beta-lactamase inhibitors and methods of use thereof | LCT, BCHE, GAA | KMT2A 1341/4885L3MBTL1 278/4885RXFP1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.